SCHEMBL1937709

SCHEMBL1937709

CCc1cnc(N2CCC(COc3c(F)cc(-c4ccc(CNC(C)(C)C)cc4)cc3F)CC2)nc1

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 17/20 0.48
FFAR4 Q5NUL3 1/20 0.35
SLC2A1 P11166 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1937372 0.91 GPR119 (0.49) GPR119FFAR4
SCHEMBL15189866 0.87 GPR119 (0.49) GPR119FFAR4
SCHEMBL1938226 0.87 GPR119 (0.53) GPR119FFAR4
SCHEMBL1937276 0.87 GPR119 (0.53) GPR119FFAR4
SCHEMBL1937700 0.85 GPR119 (0.51) GPR119FFAR4
SCHEMBL1937615 0.84 GPR119 (0.50) GPR119FFAR4
SCHEMBL1938313 0.84 GPR119 (0.49) GPR119FFAR4
SCHEMBL15196511 0.84 GPR119 (0.49) GPR119FFAR4
SCHEMBL1936232 0.84 GPR119 (0.51) GPR119
SCHEMBL1937170 0.83 GPR119 (0.51) GPR119FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331503-B1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2013-08-21 EP claimed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US claimed
JP-2011527701-A 2011-11-04 JP claimed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US claimed
EP-2331503-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-06-15 EP claimed
WO-2010006191-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-14 WO claimed
US-20160051688-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY UNIV INDIANA RES & TECH CORP (US) 2016-02-25 US disclosed
US-9145451-B2 Glucagon superfamily peptides exhbiting G protein coupled receptor activity INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-09-29 US disclosed
EP-2331503-B1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2013-08-21 EP disclosed
EP-2331503-B1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2013-08-21 EP disclosed
US-20130116172-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY MARCADIA BIOTECH, INC. (US) 2013-05-09 US disclosed
EP-2568993-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY Indiana University Research and Technology Corporation (US) 2013-03-20 EP disclosed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US disclosed
US-8334288-B2 4-phenoxymethylpiperidines as modulators of GPR119 activity IRM LLC (BM) 2012-12-18 US disclosed
WO-2011143208-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-11-17 WO disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
EP-2331503-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-06-15 EP disclosed
WO-2010006191-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116172-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY GCGR, GLP1R, GIPR GPR119 4/4885FFAR4 123/4885SLC2A1 596/4885
US-20160051688-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY GCGR, GLP1R, GIPR GPR119 4/4885FFAR4 99/4885SLC2A1 478/4885
US-20110190298-A1 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR4, GPR180 GPR119 1/4885FFAR4 50/4885SLC2A1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.